CoChat

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Heise, Tim, Mari, Andrea, DeVries, J Hans, Urva, Shweta, Li, Jing, Pratt, Edward John, Coskun, Tamer, Thomas, Melissa K, Mather, Kieren J, Haupt, Axel, Milicevic, Zvonko · 2022 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients with long-standing type 2 diabetes to achieve normoglycaemia. We aimed to understand the physiological mechanisms underlying the action of tirzepatide in type 2 diabetes. METHODS This multicentre, randomised, double-blind, parallel-arm, phase 1 study was done at two centres in Germany. Eligible patients were aged 20-74 years, had type 2 diabetes for at least 6 months, and were being treated with lifestyle advice and stable doses of metformin, with or without one additional stable dose of another oral antihyperglycaemic medicine, 3 months before study entry. Via a randomisation table, patients were randomly assigned (3:3:2) to subcutaneously receive either tirzepatide 15 mg, semaglutide 1 mg, or placebo once per week. Endpoint measurements were done at baseline and the last week of therapy (week 28). The primary endpoint was the effect of tirzepatide versus placebo on the change in clamp disposition index (combining measures of insulin secretion and sensitivity) from baseline to week 28 of treatment and was analysed in the pharmacodynamic analysis set, which comprised all randomly assigned participants who received at least one dose of a study drug and had evaluable pharmacodynamic data. Safety was analysed in the safety population, which comprised all randomly assigned participants who received at l…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00085-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 31 references

Cited by

See all 311

Metadata

Authors
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., & Milicevic, Z.
Affiliations
  • Profil Institute for Metabolic Research (DE)
  • National Research Council (IT)
  • Eli Lilly (United States) (US)
Corresponding author
Milicevic, Zvonko
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-06
Volume
10
Issue
6
Pages
418-429
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4224257527
Cited by
268
References
30
Citations by year
2026: 39 · 2025: 75 · 2024: 68 · 2023: 63 · 2022: 22
FWCI
42.22
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, semaglutide, type 2 diabetes, GIP/GLP-1 receptor agonist, islet function, insulin secretion, insulin sensitivity, m-value, glucagon, glycemic control, pharmacodynamics, metformin, glucose-dependent insulinotropic polypeptide, GLP-1 receptor agonists, subcutaneous administration
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin Resistance, Islets of Langerhans, Treatment Outcome, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00085-7
The paper
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., & Milicevic, Z. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00085-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.